 A decision analytic model compared antiemetic prophylaxis costs before and after adoption of NEPA in a hypothetical 10 million-member health plan over a 3-year time horizon.  Estimates of cancer rates and utilization of HEC and MEC therapies were derived from U.S. epidemiological and market data. Treatment costs were computed using standard prescribing dosages and U.S. drug cost listings. Average Sales Price (ASP) was used for intravenous (IV) products; Wholesale Acquisition Cost (WAC) was used for oral and transdermal products. It was assumed patients received 6 cycles of chemotherapy.
 Uptake of NEPA was estimated at 5% a year for 3 years. Market shares of competing antiemetic therapies were reduced proportionately based on their initial market segment and for each year across the time horizon.  Resulting cost estimates were calculated as total costs, per member per month (PMPM) costs, and cost per utilizing member for each 5-HT 3 -RA + NK1 combination.
 Chemotherapy-induced nausea and vomiting (CINV) is a major adverse effect of cancer treatment and can have a significant impact on patients and payers.  Current NCCN guidelines recommend a combination of a serotonin-3 receptor antagonist (5-HT 3 -RA), a substance P/neurokinin 1 (NK1) receptor antagonist, and dexamethasone for patients undergoing highly emetogenic chemotherapy (HEC) for the prevention of CINV 1 .  This same combination is also recommended in appropriate patients using moderately emetogenic chemotherapy (MEC) who are at higher risk of CINV 1 .  Netupitant/palonosetron (NEPA), a newly approved oral fixed-dose combination of a 5-HT 3 -RA and an NK1 for the prevention of CINV in patients receiving HEC and MEC regimens, is currently recommended by the NCCN guidelines. .
The purpose of this study was to estimate the budget impact of adopting NEPA from the perspective of a large U.S. health plan.
 Results of the model indicate that adoption of NEPA for the prevention of CINV will have a relatively neutral impact on a U.S. health plan budget.  The budget impact model only considers the costs of the medications, and does not consider the clinical benefits of the regimens. Given the expected effectiveness of NEPA, other savings such as reduced incidence of CINV may further contribute to overall savings for health plans and patients. 
EXAMINING THE BUDGET IMPACT OF ADOPTING NETUPITANT/PALONOSETRON FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN A LARGE U.S. HEALTH PLAN

Figure 2. Annual Plan Costs Over a 3 Year Period
Model Population  A total of 54,000 patients with cancer were identified in the model scenario.  Of these, 9,882 (18.3%) would receive HEC and 3,949 (17.3%) would receive MEC requiring combination therapy, for a total of 13,830 patients eligible for NEPA (Figure 1 ).
Annual Plan Costs
 Treatment for the prevention of CINV prior to the adoption of NEPA was estimated as costing over $42 million (Figure 2 ).  Following the adoption of NEPA, cumulative costs were reduced by $652,000 by the end of year 3 (Figure 2 ).
Per Member Per Month Costs
 The addition of NEPA resulted in a small positive impact (savings) on PMPM costs over the course of the 3 year time period.  PMPM estimates showed a cumulative savings of $0.002 in year 1, $0.003 in year 2, and $0.005 in year 3 (Table 1) .
Per Utilizing Member Costs  Only two other regimens were less expensive than NEPA when costs were evaluated on a per utilizing member basis (Figure 3 ).  NEPA was less expensive than either combination of Aloxi + Emend (palonosetron and fosaprepitant or palonosetron and aprepitant).  Results of the model are based on current pricing of medications. All such pricing is subject to change.  Model assumptions are based on patients remaining on the same CINV prevention regimens throughout chemotherapy cycles, and do not take into consideration the costs for patients who may switch therapy.  Differences between the costs reported in the abstract and those seen in this poster reflect price changes for several antiemetics that occurred between the publication of the abstract and the presentation of the poster.
